Payment overview · 2025
General Payments
$2,147.34
87 reported records · 24 companies
Healthcare provider profile · identity verified
William P Jacks, MD
Allopathic & Osteopathic Physicians|Family Medicine · N LAS VEGAS, NV · NPI 1659353878
Verified facts
What the public records show
CMS Open Payments records show William P Jacks, MD received $2,147.34 in general payments during 2025 across 87 reported records.
AstraZeneca Pharmaceuticals LP accounted for 23.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 35 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 199 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 134 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 356 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 139 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $504.10 | 23.5% | 16 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $313.32 | 14.6% | 11 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $206.68 | 9.6% | 8 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $151.11 | 7.0% | 9 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $148.08 | 6.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $141.98 | 6.6% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $85.34 | 4.0% | 5 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $83.51 | 3.9% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $78.68 | 3.7% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $78.44 | 3.6% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $77.87 | 3.6% | 3 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $48.86 | 2.3% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $25.14 | 1.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $24.84 | 1.2% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $24.35 | 1.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.76 | 1.1% | 1 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $19.09 | 0.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $18.86 | 0.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.06 | 0.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $16.44 | 0.8% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $16.23 | 0.8% | 1 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $15.43 | 0.7% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $14.63 | 0.7% | 1 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $13.54 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,147.34 | 87 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $289.79 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $206.68 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $202.08 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $151.11 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $142.70 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $141.98 | 7 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $94.23 | 5 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $83.51 | 4 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $78.68 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $78.68 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $78.44 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $77.87 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $68.18 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $68.18 | 4 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $48.92 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $48.86 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $47.75 | 2 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $25.14 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $24.84 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $24.35 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $22.76 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $20.75 | 2 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $19.09 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.91 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $17.16 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $16.23 | 1 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $13.54 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $12.23 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 139 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 213 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 134 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 52 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 199 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 356 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
52 | 26 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
33 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
213 | 84 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
134 | 48 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
134 | 48 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
199 | 40 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
134 | 40 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
356 | 85 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
139 | 48 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1331 | 516 |
| Metformin Hcl | Metformin Hcl | 1001 | 375 |
| Lisinopril | Lisinopril | 733 | 265 |
| Losartan Potassium | Losartan Potassium | 607 | 231 |
| Levothyroxine Sodium | Levothyroxine Sodium | 576 | 194 |
| Amlodipine Besylate | Amlodipine Besylate | 557 | 213 |
| Gabapentin | Gabapentin | 543 | 205 |
| Omeprazole | Omeprazole | 527 | 194 |
| Simvastatin | Simvastatin | 461 | 160 |
| Montelukast Sodium | Montelukast Sodium | 438 | 160 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 410 | 150 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 386 | 112 |
| Alendronate Sodium | Alendronate Sodium | 384 | 118 |
| Famotidine | Famotidine | 382 | 139 |
| Tamsulosin Hcl | Tamsulosin Hcl | 368 | 134 |
| Ozempic | Semaglutide | 356 | 85 |
| Pantoprazole Sodium | Pantoprazole Sodium | 327 | 122 |
| Glimepiride | Glimepiride | 304 | 102 |
| Diclofenac Sodium | Diclofenac Sodium | 301 | 118 |
| Metoprolol Succinate | Metoprolol Succinate | 299 | 113 |
| Metoprolol Tartrate | Metoprolol Tartrate | 281 | 92 |
| Hydrochlorothiazide | Hydrochlorothiazide | 280 | 102 |
| Ibuprofen | Ibuprofen | 265 | 112 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 264 | 78 |
| Trazodone Hcl | Trazodone Hcl | 245 | 98 |
| Fluticasone Propionate | Fluticasone Propionate | 232 | 95 |
| Ezetimibe | Ezetimibe | 228 | 71 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 220 | 76 |
| Farxiga | Dapagliflozin Propanediol | 213 | 84 |
| Donepezil Hcl | Donepezil Hcl | 210 | 64 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 204 | 99 |
| Mounjaro | Tirzepatide | 199 | 40 |
| Carvedilol | Carvedilol | 198 | 81 |
| Fenofibrate | Fenofibrate Nanocrystallized | 186 | 57 |
| Naproxen | Naproxen | 186 | 77 |
| Sertraline Hcl | Sertraline Hcl | 179 | 61 |
| Furosemide | Furosemide | 162 | 62 |
| Allopurinol | Allopurinol | 159 | 55 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 157 | 61 |
| Zolpidem Tartrate | Zolpidem Tartrate | 146 | 27 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 144 | 49 |
| Azithromycin | Azithromycin | 142 | 118 |
| Eliquis | Apixaban | 139 | 48 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 136 | 48 |
| Buspirone Hcl | Buspirone Hcl | 135 | 44 |
| Jardiance | Empagliflozin | 134 | 48 |
| Trulicity | Dulaglutide | 134 | 40 |
| Meclizine Hcl | Meclizine Hcl | 132 | 49 |
| Methylprednisolone | Methylprednisolone | 131 | 102 |
| Pioglitazone Hcl | Pioglitazone Hcl | 123 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 116 | 45 |
| Glipizide | Glipizide | 112 | 39 |
| Tizanidine Hcl | Tizanidine Hcl | 111 | 29 |
| Finasteride | Finasteride | 107 | 43 |
| Pravastatin Sodium | Pravastatin Sodium | 107 | 35 |
| Januvia | Sitagliptin Phosphate | 105 | 35 |
| Citalopram Hbr | Citalopram Hydrobromide | 101 | 38 |
| Alprazolam | Alprazolam | 98 | 24 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 93 | 33 |
| Bumetanide | Bumetanide | 92 | 40 |
| Telmisartan | Telmisartan | 92 | 28 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 88 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 40 |
| Valacyclovir | Valacyclovir Hcl | 84 | 25 |
| Dicyclomine Hcl | Dicyclomine Hcl | 81 | 37 |
| Meloxicam | Meloxicam | 81 | 34 |
| Atenolol | Atenolol | 80 | 29 |
| Clonazepam | Clonazepam | 79 | 18 |
| Clonidine Hcl | Clonidine Hcl | 78 | 28 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 77 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 27 |
| Lidocaine | Lidocaine | 75 | 33 |
| Celecoxib | Celecoxib | 71 | 28 |
| Potassium Chloride | Potassium Chloride | 71 | 32 |
| Hydralazine Hcl | Hydralazine Hcl | 65 | 22 |
| Novolog Flexpen | Insulin Aspart | 64 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 63 | 24 |
| Baclofen | Baclofen | 62 | 26 |
| Cilostazol | Cilostazol | 62 | 18 |
| Memantine Hcl | Memantine Hcl | 62 | 18 |
| Fenofibrate | Fenofibrate | 61 | 20 |
| Tramadol Hcl | Tramadol Hcl | 60 | 29 |
| Bupropion Hcl Sr | Bupropion Hcl | 59 | 25 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | 11 |
| Lovastatin | Lovastatin | 57 | 19 |
| Oxybutynin Chloride | Oxybutynin Chloride | 57 | 21 |
| Tradjenta | Linagliptin | 54 | 23 |
| Linzess | Linaclotide | 52 | 26 |
| Folic Acid | Folic Acid | 51 | 20 |
| Humalog Kwikpen U-100 | Insulin Lispro | 51 | 21 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 50 | 23 |
| Mirtazapine | Mirtazapine | 48 | 21 |
| Sumatriptan Succinate | Sumatriptan Succinate | 48 | 18 |
| Ventolin Hfa | Albuterol Sulfate | 48 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 23 |
| Promethazine Hcl | Promethazine Hcl | 47 | 36 |
| Enalapril Maleate | Enalapril Maleate | 46 | 15 |
| Nifedipine Er | Nifedipine | 46 | 20 |
| Bupropion Xl | Bupropion Hcl | 45 | 14 |
| Metformin Hcl Er | Metformin Hcl | 45 | 14 |
| Megestrol Acetate | Megestrol Acetate | 41 | 18 |
| Valsartan | Valsartan | 41 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 40 | 17 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 39 | 15 |
| Fluconazole | Fluconazole | 38 | 22 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 23 |
| Spironolactone | Spironolactone | 38 | 16 |
| Propranolol Hcl | Propranolol Hcl | 37 | 11 |
| Sildenafil Citrate | Sildenafil Citrate | 37 | 18 |
| Tresiba Flextouch U-100 | Insulin Degludec | 37 | 12 |
| Azelastine Hcl | Azelastine Hcl | 36 | 14 |
| Mupirocin | Mupirocin | 36 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | 14 |
| Nitroglycerin | Nitroglycerin | 35 | 12 |
| Topiramate | Topiramate | 35 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 34 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 33 | 29 |
| Myrbetriq | Mirabegron | 33 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 22 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Ondansetron Odt | Ondansetron | 32 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | 11 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 30 | 14 |
| Hydrocortisone | Hydrocortisone | 30 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 30 | 14 |
| Pregabalin | Pregabalin | 29 | 11 |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 28 | 11 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 26 | suppressed |
| Latanoprost | Latanoprost | 26 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 25 | 11 |
| Methotrexate | Methotrexate Sodium | 25 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 25 | 12 |
| Fenofibrate | Fenofibrate,micronized | 24 | 11 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 24 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 24 | suppressed |
| Lansoprazole | Lansoprazole | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Prednisone | Prednisone | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 22 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 22 | 11 |
| Vascepa | Icosapent Ethyl | 22 | suppressed |
| Amoxicillin | Amoxicillin | 21 | 16 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 21 | suppressed |
| Glipizide Er | Glipizide | 21 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 21 | suppressed |
| Testosterone | Testosterone | 21 | suppressed |
| Belsomra | Suvorexant | 20 | suppressed |
| Cromolyn Sodium | Cromolyn Sodium | 20 | 12 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 20 | 11 |
| Ibandronate Sodium | Ibandronate Sodium | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | 14 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 20 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 19 | 12 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | 12 |
| Clobetasol Propionate | Clobetasol Propionate | 18 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Creon | Lipase/Protease/Amylase | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 11 |
| Nortriptyline Hcl | Nortriptyline Hcl | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Scopolamine | Scopolamine | 17 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 17 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 15 |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 16 | 12 |
| Arnuity Ellipta | Fluticasone Furoate | 15 | suppressed |
| Clotrimazole | Clotrimazole | 15 | suppressed |
| Digoxin | Digoxin | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 14 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Fluocinonide | Fluocinonide | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Procto-Med Hc | Hydrocortisone | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Rexulti | Brexpiprazole | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 11 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Butalbital-Aspirin-Caffeine | Butalbital/Aspirin/Caffeine | 11 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | 11 |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lactulose | Lactulose | 11 | suppressed |
| Levoxyl | Levothyroxine Sodium | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 11 | suppressed |
| Prolia | Denosumab | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 11 | suppressed |
| Timolol Maleate | Timolol Maleate | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,147.34 · 87 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AFREZZA, AIRSUPRA, APTIMA, Auvelity, BREZTRI, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, General - Pain Management, JARDIANCE, KISUNLA, Kerendia, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, Symbravo, TRELEGY ELLIPTA, TZIELD, VERQUVO, VOQUEZNA, Veozah, Wegovy, XIFAXAN, ZAVZPRET, ZENPEP, ZEPBOUND | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error